Article
A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.
Medical oncology (Northwood, London, England) - 22 Jul 2026
Chakraborty Sourav, Shenoy Priti S, Nath Sreyashi, Panda Tushar Ranjan, Bhat Arpita, Sakpal Asmita, Mehrotra Megha, Singh Prerna, Patra Malay, Ray Pritha
Abstract excerpt
Therapy resistance is a complex and multifaceted pathological phenomenon, often driven by mutations in the p53 tumor suppressor gene. This ultimately causes tumor recurrence thereby adversely affecting patient prognosis. Therefore, development of effective chemotherapeutic agents that simultaneously inhibit tumor proliferation and overcome resistance mechanisms is of paramount importance. Recently, we identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.